Researcher
Eric Verdin
Last updated Sat May 30 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Background
Eric Verdin has been President and CEO of the Buck Institute for Research on Aging since 2016. Before that he led the Verdin Lab at the Gladstone Institutes (UCSF affiliate) and trained at the NIH.
Lines of work
- Sirtuin biology: mechanistic work on SIRT3 in mitochondrial acetylation; SIRT1 in metabolic regulation.
- β-hydroxybutyrate as a signalling molecule beyond fuel — HDAC inhibition, NLRP3 inflammasome inhibition; the biology behind ketogenic-diet effects.
- NAD+ metabolism: how NAD+ decline affects sirtuin activity, mitochondrial function.
- Immune aging: T-cell exhaustion and senescence; how immune decline drives systemic aging.
Public communication
A frequent speaker on geroscience translation; advocate for evidence-based caution about consumer longevity products without inhibiting the field’s momentum.
Related entries
Sirtuins, NAD+ precursors, Ketogenic diet, NLRP3 inflammasome.
References
- Newman, J. C. & Verdin, E. β-Hydroxybutyrate: a signaling metabolite. Annu. Rev. Nutr. 37, 51–76 (2017).